cardiovascular risk
Coverage of cardiovascular risk in the Nexus archive.
- STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
Eli Lilly's retatrutide, a next-generation obesity drug, showed significant weight loss in a Phase 3 study of 2,000 participants with severe obesity and heart disease, but did not demonstrate a statistically significant reduction in cardiovascular risk. The trial was not designed to assess cardiovascular outcomes, and event rates were lower than expected.
- Least fit people need to do more exercise than fittest to get same benefit – study
A study found that people who are least fit need to do 30-50 minutes more exercise a week than the fittest to get the same reduction in cardiovascular risk. The research examined data from over 17,000 British adults participating in the UK Biobank study. The findings appear to challenge previous studies, with some experts calling aspects of it 'misguided'.